- Home
- CRNX
as 03-28-2025 4:00pm EST
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 5.2B | IPO Year: | 2018 |
| Target Price: | $73.36 | AVG Volume (30 days): | 937.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.69 | EPS Growth: | N/A |
| 52 Week Low/High: | $31.84 - $62.53 | Next Earning Date: | 05-08-2025 |
| Revenue: | $1,039,000 | Revenue Growth: | -74.11% |
| Revenue Growth (this year): | 394.51% | Revenue Growth (next year): | 699.82% |
Stock Insider Trading Activity of Crinetics Pharmaceuticals Inc. (CRNX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Struthers Richard Scott | CRNX | President & CEO | Mar 19 '25 | Sell | $34.50 | 17,338 | $593,016.96 | 330,022 | |
| Pizzuti Dana | CRNX | Chief Med and Dev Officer | Mar 19 '25 | Sell | $34.50 | 2,515 | $86,021.37 | 72,360 | |
| Betz Stephen F. | CRNX | Chief Scientific Officer | Mar 19 '25 | Sell | $34.50 | 5,770 | $197,352.96 | 108,588 | |
| Pizzuti Dana | CRNX | Chief Med and Dev Officer | Feb 3 '25 | Sell | $39.07 | 5,000 | $195,350.00 | 72,360 | |
| Pizzuti Dana | CRNX | Chief Med and Dev Officer | Jan 3 '25 | Sell | $52.09 | 15,000 | $781,350.00 | 72,360 |
Latest Crinetics Pharmaceuticals Inc. News
CRNX Breaking Stock News: Dive into CRNX Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
Crinetics Pharmaceuticals Says EMA Validates Marketing Authorization Application for Acromegaly Drug
GlobeNewswire
a day ago
Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly
MT Newswires
4 days ago
Stifel Initiates Crinetics Pharmaceuticals at Buy With $60 Price Target
GlobeNewswire
18 days ago
Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
a month ago
Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
MT Newswires
a month ago
Crinetics Pharmaceuticals Q4 Net Loss Narrows
GlobeNewswire
a month ago
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Insider Monkey
a month ago
Is Crinetics Pharmaceuticals (CRNX) the Worst Performing Mid Cap Stock to Buy According to Analysts?
Compare CRNX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRNX Crinetics Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.